Log In
BCIQ
Print this Print this
 

SURVEYOR Scan K-RAS kit

  Manage Alerts
Collapse Summary General Information
Company Transgenomic Inc.
DescriptionKit to detect mutations in K-Ras associated with drug-resistant tumors
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect mutations in K-Ras associated with drug-resistant tumors.
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$4.3M

$4.3M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/02/2014

$4.3M

$4.3M

0

Get a free BioCentury trial today